RYTELO® (Imetelstat)

The FDA on June 6, 2024, approved RYTELO® an oligonucleotide telomerase inhibitor, for adults with low- to intermediate-1 risk MyeloDysplastic Syndromes (MDS) with transfusion-dependent anemia requiring four or more red blood cell units over 8 weeks, who have not responded to, or have lost response to, or are ineligible for Erythropoiesis-Stimulating Agents (ESAs). RYTELO® is a product of Geron Corporation.